. Author manuscript; available in PMC: 2020 Oct 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):124–130. doi: 10.1097/QAI.0000000000002120

Table 3.

Missed clinic visits during the first six and twelve months of MDR-TB treatment, among all participants and by HIV co-infection status (n=191).

	Total Cohort	HIV+ (n=138)	HIV− (n=53)	p- value^*
	n (%)	n (%)	n (%)	p- value^*
Number of missed visits - first 6 months
MDR-TB treatment				0.15
0	149 (78)	103 (75)	46 (87)
1	23 (12)	17 (12)	6 (11)
2	7 (4)	7 (5)	0 (0)
≥ 3	12 (6)	11 (8.0)	1 (2)
Number of missed visits - first 12 months
MDR-TB treatment				0.30
0	124 (65)	84 (61)	40 (76)
1	29 (15)	24 (17)	5 (9)
2	13 (7)	11 (8)	2 (4)
≥ 3	25 (13)	19 (14)	6 (11)

MDR-TB: Multidrug-resistant tuberculosis; HIV: Human immunodeficiency virus

Fisher's exact test